Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Aloxireg

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Helsinn, Magnapharm Strike Long-Term Deal For AKYNZEO & ALOXI
    Helsinn, Magnapharm Strike Long-Term Deal For AKYNZEO & ALOXI

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236025/0/en/Helsinn-and-MagnaPharm-enter-long-term-agreement-for-AKYNZEO-and-ALOXI-across-five-Central-and-Eastern-European-countries.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Helsinn, ESTEVE Extend AKYNZEO® And ALOXI® Agreement To Austria
    Helsinn, ESTEVE Extend AKYNZEO® And ALOXI® Agreement To Austria

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234320/0/en/Helsinn-and-ESTEVE-expand-their-partnership-extending-the-Distribution-and-Licence-Agreement-for-AKYNZEO-and-ALOXI-to-Austria.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Shilpa Medicare Aims For US Approval Of Chemo Nausea Drug
    Shilpa Medicare Aims For US Approval Of Chemo Nausea Drug

    09 Jan 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/shilpa-medicare-aims-for-us-approval-of-chemo-nausea-drug-18815

    INDPHARMAPOST
    09 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.